This report provides an analysis of the Global Biliary Tract Cancer industry in terms of market segmentation By Indication (Extrahepatic Bile Duct Cancer, Intrahepatic Bile Duct Cancer), By Therapeutics (Gemcitabine + Cisplatin, Gemcitabine + Cisplatin + Other targeted therapies, Gemcitabine, Other targeted therapies, and Gemcitabine + Other chemotherapy combinations) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.
The Global Biliary Tract Cancer market showcased growth at a CAGR of 9.53% during 2020-2023. The market was valued at USD 696.75 Million in 2023 which is expected to reach USD 1.42 billion in 2030.
Biliary tract cancer is a relatively uncommon malignancy, accounting for approximately 3% of all gastrointestinal cancers worldwide. This translates to a significant number of cases when considering the global population. Countries in Southeast Asia, particularly those with high rates of parasitic infections like Clonorchis sinensis and Opisthorchis viverrini, have significantly higher rates of biliary tract cancer. These infections cause chronic inflammation of the bile ducts, which can increase the risk of cancer development. Other factors contributing to the higher incidence in this region include environmental pollutants, dietary habits, and genetic susceptibility.
This market has been witnessing gradual growth due to rising incidence rates, advancements in diagnostic technologies, and the development of targeted therapies. However, challenges persist due to the rarity of the disease, which limits the availability of large-scale clinical data and complicates drug development efforts.
The limited availability of effective treatments for biliary tract cancer, coupled with the low survival rates associated with the disease, has created a significant and urgent need for the development of innovative therapeutic approaches.
The Global Biliary Tract Cancer market showcased growth at a CAGR of 9.53% during 2020-2023. The market was valued at USD 696.75 Million in 2023 which is expected to reach USD 1.42 billion in 2030.
Biliary tract cancer is a relatively uncommon malignancy, accounting for approximately 3% of all gastrointestinal cancers worldwide. This translates to a significant number of cases when considering the global population. Countries in Southeast Asia, particularly those with high rates of parasitic infections like Clonorchis sinensis and Opisthorchis viverrini, have significantly higher rates of biliary tract cancer. These infections cause chronic inflammation of the bile ducts, which can increase the risk of cancer development. Other factors contributing to the higher incidence in this region include environmental pollutants, dietary habits, and genetic susceptibility.
This market has been witnessing gradual growth due to rising incidence rates, advancements in diagnostic technologies, and the development of targeted therapies. However, challenges persist due to the rarity of the disease, which limits the availability of large-scale clinical data and complicates drug development efforts.
The limited availability of effective treatments for biliary tract cancer, coupled with the low survival rates associated with the disease, has created a significant and urgent need for the development of innovative therapeutic approaches.
Scope of the Report
- The report analyses the Biliary Tract Cancer Market by Value ( USD Million).
- The report analyses the Biliary Tract Cancer Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
- The report presents the analysis of Biliary Tract Cancer Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
- The report analyses the Biliary Tract Cancer Market By Indication (Extrahepatic Bile Duct Cancer, Intrahepatic Bile Duct Cancer)
- The report analyses the Biliary Tract Cancer Market By Therapeutics (Gemcitabine + Cisplatin, Gemcitabine + Cisplatin + Other targeted therapies, Gemcitabine, Other targeted therapies, and Gemcitabine + Other chemotherapy combinations).
- The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Indication, and By Therapeutics.
- Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Johnson & Johnson, Sanofi, Novartis, Pfizer, Bayer AG, Merck & Co., Inc., Teva Pharmaceuticals, Eli Lily & Co, Bristol Myers Squibb, and F. Hoffmann-La Roche AG.
Table of Contents
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
1.2 Executive Summary
1.3 Research Methodology
2. Analyst Recommendations
2.1 Develop Comprehensive Care Protocols
2.2 Improve Access to Treatments
2.2 Improve Access to Treatments
3. Global Biliary Tract Cancer Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Biliary Tract Cancer Market
3.2 Global Prevalence of Gallbladder and biliary tract cancer, 2021
3.3 Global Incidence of Gallbladder and biliary tract cancer, 2021
3.4 Total Incident Cases of Biliary tract cancers in the 7 Major Markets 2020-2024
3.5 Global Biliary Tract Cancer Market: Dashboard
3.6 Global Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
3.7 Global Biliary Tract Cancer Market: Market Value Assessment
3.8 Assessment Degree of Impact of COVID-19 on Biliary Tract Cancer Market
3.9 Global Biliary Tract Cancer Market Segmentation: By Indication
3.9.1 Global Biliary Tract Cancer Market, By Indication Overview
3.9.2 Global Biliary Tract Cancer Market Attractiveness Index, By Indication
3.9.3 Global Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.9.4 Global Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.10 Global Biliary Tract Cancer Market Segmentation: By Therapeutics
3.10.1 Global Biliary Tract Cancer Market, By Therapeutics Overview
3.10.2 Global Biliary Tract Cancer Market Attractiveness Index, By Therapeutics
3.10.3 Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
3.10.4 Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
3.10.5 Global Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
3.10.6 Global Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
3.10.7 Global Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
3.2 Global Prevalence of Gallbladder and biliary tract cancer, 2021
3.3 Global Incidence of Gallbladder and biliary tract cancer, 2021
3.4 Total Incident Cases of Biliary tract cancers in the 7 Major Markets 2020-2024
3.5 Global Biliary Tract Cancer Market: Dashboard
3.6 Global Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
3.7 Global Biliary Tract Cancer Market: Market Value Assessment
3.8 Assessment Degree of Impact of COVID-19 on Biliary Tract Cancer Market
3.9 Global Biliary Tract Cancer Market Segmentation: By Indication
3.9.1 Global Biliary Tract Cancer Market, By Indication Overview
3.9.2 Global Biliary Tract Cancer Market Attractiveness Index, By Indication
3.9.3 Global Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.9.4 Global Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.10 Global Biliary Tract Cancer Market Segmentation: By Therapeutics
3.10.1 Global Biliary Tract Cancer Market, By Therapeutics Overview
3.10.2 Global Biliary Tract Cancer Market Attractiveness Index, By Therapeutics
3.10.3 Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
3.10.4 Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
3.10.5 Global Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
3.10.6 Global Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
3.10.7 Global Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
4. Biliary Tract Cancer Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
4.2 Regional Snapshot
5. Americas Biliary Tract Cancer Market: Historic and Forecast
5.1 Americas Biliary Tract Cancer Market: Snapshot
5.2 Americas Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.3 Americas Biliary Tract Cancer Market: Key Factors
5.4 Americas Biliary Tract Cancer Market: Segment Analysis
5.5 Americas Biliary Tract Cancer Market Segmentation: By Indication
5.5.1 Americas Biliary Tract Cancer Market, By Indication Overview
5.5.2 Americas Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.5.3 Americas Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.6 Americas Biliary Tract Cancer Market Segmentation: By Therapeutics
5.6.1 Americas Biliary Tract Cancer Market, By Therapeutics Overview
5.6.2 Americas Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
5.6.3 Americas Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
5.6.4 Americas Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
5.6.5 Americas Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
5.6.6 Americas Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
5.7 Americas Biliary Tract Cancer Market Segmentation: By Country
5.7.1 Americas Biliary Tract Cancer Market, by Country Overview
5.7.2 United States Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.7.2.1 United States Biliary Tract Cancer Market, By Indication
5.7.2.2 United States Biliary Tract Cancer Market, By Therapeutics
5.7.3 Canada Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.7.3.1 Canada Biliary Tract Cancer Market, By Indication
5.7.3.2 Canada Biliary Tract Cancer Market, By Therapeutics
5.7.4 Rest of Americas Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.7.4.1 Rest of Americas Biliary Tract Cancer Market, By Indication
5.7.4.2 Rest of Americas Biliary Tract Cancer Market, By Therapeutics
5.2 Americas Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.3 Americas Biliary Tract Cancer Market: Key Factors
5.4 Americas Biliary Tract Cancer Market: Segment Analysis
5.5 Americas Biliary Tract Cancer Market Segmentation: By Indication
5.5.1 Americas Biliary Tract Cancer Market, By Indication Overview
5.5.2 Americas Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.5.3 Americas Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.6 Americas Biliary Tract Cancer Market Segmentation: By Therapeutics
5.6.1 Americas Biliary Tract Cancer Market, By Therapeutics Overview
5.6.2 Americas Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
5.6.3 Americas Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
5.6.4 Americas Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
5.6.5 Americas Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
5.6.6 Americas Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
5.7 Americas Biliary Tract Cancer Market Segmentation: By Country
5.7.1 Americas Biliary Tract Cancer Market, by Country Overview
5.7.2 United States Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.7.2.1 United States Biliary Tract Cancer Market, By Indication
5.7.2.2 United States Biliary Tract Cancer Market, By Therapeutics
5.7.3 Canada Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.7.3.1 Canada Biliary Tract Cancer Market, By Indication
5.7.3.2 Canada Biliary Tract Cancer Market, By Therapeutics
5.7.4 Rest of Americas Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.7.4.1 Rest of Americas Biliary Tract Cancer Market, By Indication
5.7.4.2 Rest of Americas Biliary Tract Cancer Market, By Therapeutics
6. Europe Biliary Tract Cancer Market: Historic and Forecast
6.1 Europe Biliary Tract Cancer Market: Snapshot
6.2 Europe Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.3 Europe Biliary Tract Cancer Market: Key Factors
6.4 Europe Biliary Tract Cancer Market: Segment Analysis
6.5 Europe Biliary Tract Cancer Market Segmentation: By Indication
6.5.1 Europe Biliary Tract Cancer Market, By Indication Overview
6.5.2 Europe Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.5.3 Europe Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.6 Europe Biliary Tract Cancer Market Segmentation: By Therapeutics
6.6.1 Europe Biliary Tract Cancer Market, By Therapeutics Overview
6.6.2 Europe Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
6.6.3 Europe Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
6.6.4 Europe Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
6.6.5 Europe Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
6.6.6 Europe Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
6.7 Europe Biliary Tract Cancer Market Segmentation: By Country
6.7.1 Europe Biliary Tract Cancer Market, by Country Overview
6.7.2 Germany Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.2.1 Germany Biliary Tract Cancer Market, By Indication
6.7.2.2 Germany Biliary Tract Cancer Market, By Therapeutics
6.7.3 United Kingdom Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.3.1 United Kingdom Biliary Tract Cancer Market, By Indication
6.7.3.2 United Kingdom Biliary Tract Cancer Market, By Therapeutics
6.7.4 France Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.4.1 France Biliary Tract Cancer Market, By Indication
6.7.4.2 France Biliary Tract Cancer Market, By Therapeutics
6.7.5 Italy Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.5.1 Italy Biliary Tract Cancer Market, By Indication
6.7.5.2 Italy Biliary Tract Cancer Market, By Therapeutics
6.7.6 Spain Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.6.1 Spain Biliary Tract Cancer Market, By Indication
6.7.6.2 Spain Biliary Tract Cancer Market, By Therapeutics
6.7.7 Rest of Europe Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.7.1 Rest of Europe Biliary Tract Cancer Market, By Indication
6.7.7.2 Rest of Europe Biliary Tract Cancer Market, By Therapeutics
6.2 Europe Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.3 Europe Biliary Tract Cancer Market: Key Factors
6.4 Europe Biliary Tract Cancer Market: Segment Analysis
6.5 Europe Biliary Tract Cancer Market Segmentation: By Indication
6.5.1 Europe Biliary Tract Cancer Market, By Indication Overview
6.5.2 Europe Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.5.3 Europe Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.6 Europe Biliary Tract Cancer Market Segmentation: By Therapeutics
6.6.1 Europe Biliary Tract Cancer Market, By Therapeutics Overview
6.6.2 Europe Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
6.6.3 Europe Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
6.6.4 Europe Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
6.6.5 Europe Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
6.6.6 Europe Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
6.7 Europe Biliary Tract Cancer Market Segmentation: By Country
6.7.1 Europe Biliary Tract Cancer Market, by Country Overview
6.7.2 Germany Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.2.1 Germany Biliary Tract Cancer Market, By Indication
6.7.2.2 Germany Biliary Tract Cancer Market, By Therapeutics
6.7.3 United Kingdom Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.3.1 United Kingdom Biliary Tract Cancer Market, By Indication
6.7.3.2 United Kingdom Biliary Tract Cancer Market, By Therapeutics
6.7.4 France Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.4.1 France Biliary Tract Cancer Market, By Indication
6.7.4.2 France Biliary Tract Cancer Market, By Therapeutics
6.7.5 Italy Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.5.1 Italy Biliary Tract Cancer Market, By Indication
6.7.5.2 Italy Biliary Tract Cancer Market, By Therapeutics
6.7.6 Spain Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.6.1 Spain Biliary Tract Cancer Market, By Indication
6.7.6.2 Spain Biliary Tract Cancer Market, By Therapeutics
6.7.7 Rest of Europe Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.7.7.1 Rest of Europe Biliary Tract Cancer Market, By Indication
6.7.7.2 Rest of Europe Biliary Tract Cancer Market, By Therapeutics
7. Asia Pacific Biliary Tract Cancer Market: Historic and Forecast
7.1 Asia Pacific Biliary Tract Cancer Market: Snapshot
7.2 Asia Pacific Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.3 Asia Pacific Biliary Tract Cancer Market: Key Factors
7.4 Asia Pacific Biliary Tract Cancer Market: Segment Analysis
7.5 Asia Pacific Biliary Tract Cancer Market Segmentation: By Indication
7.5.1 Asia Pacific Biliary Tract Cancer Market, By Indication Overview
7.5.2 Asia Pacific Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.5.3 Asia Pacific Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.6 Asia Pacific Biliary Tract Cancer Market Segmentation: By Therapeutics
7.6.1 Asia Pacific Biliary Tract Cancer Market, By Therapeutics Overview
7.6.2 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
7.6.3 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
7.6.4 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
7.6.5 Asia Pacific Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
7.6.6 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
7.7 Asia Pacific Biliary Tract Cancer Market Segmentation: By Country
7.7.1 Asia Pacific Biliary Tract Cancer Market, by Country Overview
7.7.2 China Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.2.1 China Biliary Tract Cancer Market, By Indication
7.7.2.2 China Biliary Tract Cancer Market, By Therapeutics
7.7.3 Japan Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.3.1 Japan Biliary Tract Cancer Market, By Indication
7.7.3.2 Japan Biliary Tract Cancer Market, By Therapeutics
7.7.4 India Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.4.1 India Biliary Tract Cancer Market, By Indication
7.7.4.2 India Biliary Tract Cancer Market, By Therapeutics
7.7.5 Rest of Asia Pacific Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.5.1 Rest of Asia Pacific Biliary Tract Cancer Market, By Indication
7.7.5.2 Rest of Asia Pacific Biliary Tract Cancer Market, By Therapeutics
7.2 Asia Pacific Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.3 Asia Pacific Biliary Tract Cancer Market: Key Factors
7.4 Asia Pacific Biliary Tract Cancer Market: Segment Analysis
7.5 Asia Pacific Biliary Tract Cancer Market Segmentation: By Indication
7.5.1 Asia Pacific Biliary Tract Cancer Market, By Indication Overview
7.5.2 Asia Pacific Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.5.3 Asia Pacific Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.6 Asia Pacific Biliary Tract Cancer Market Segmentation: By Therapeutics
7.6.1 Asia Pacific Biliary Tract Cancer Market, By Therapeutics Overview
7.6.2 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
7.6.3 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
7.6.4 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
7.6.5 Asia Pacific Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
7.6.6 Asia Pacific Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
7.7 Asia Pacific Biliary Tract Cancer Market Segmentation: By Country
7.7.1 Asia Pacific Biliary Tract Cancer Market, by Country Overview
7.7.2 China Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.2.1 China Biliary Tract Cancer Market, By Indication
7.7.2.2 China Biliary Tract Cancer Market, By Therapeutics
7.7.3 Japan Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.3.1 Japan Biliary Tract Cancer Market, By Indication
7.7.3.2 Japan Biliary Tract Cancer Market, By Therapeutics
7.7.4 India Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.4.1 India Biliary Tract Cancer Market, By Indication
7.7.4.2 India Biliary Tract Cancer Market, By Therapeutics
7.7.5 Rest of Asia Pacific Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.7.5.1 Rest of Asia Pacific Biliary Tract Cancer Market, By Indication
7.7.5.2 Rest of Asia Pacific Biliary Tract Cancer Market, By Therapeutics
8. Middle East and Africa Biliary Tract Cancer Market: Historic and Forecast
8.1 Middle East and Africa Biliary Tract Cancer Market: Snapshot
8.2 Middle East and Africa Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.3 Middle East and Africa Biliary Tract Cancer Market: Key Factors
8.4 Middle East and Africa Biliary Tract Cancer Market: Segment Analysis
8.5 Middle East and Africa Biliary Tract Cancer Market Segmentation: By Indication
8.5.1 Middle East and Africa Biliary Tract Cancer Market, By Indication Overview
8.5.2 Middle East and Africa Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.5.3 Middle East and Africa Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.6 Middle East and Africa Biliary Tract Cancer Market Segmentation: By Therapeutics
8.6.1 Middle East and Africa Biliary Tract Cancer Market, By Therapeutics Overview
8.6.2 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
8.6.3 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
8.6.4 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
8.6.5 Middle East and Africa Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
8.6.6 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
8.2 Middle East and Africa Biliary Tract Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.3 Middle East and Africa Biliary Tract Cancer Market: Key Factors
8.4 Middle East and Africa Biliary Tract Cancer Market: Segment Analysis
8.5 Middle East and Africa Biliary Tract Cancer Market Segmentation: By Indication
8.5.1 Middle East and Africa Biliary Tract Cancer Market, By Indication Overview
8.5.2 Middle East and Africa Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.5.3 Middle East and Africa Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.6 Middle East and Africa Biliary Tract Cancer Market Segmentation: By Therapeutics
8.6.1 Middle East and Africa Biliary Tract Cancer Market, By Therapeutics Overview
8.6.2 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
8.6.3 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
8.6.4 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
8.6.5 Middle East and Africa Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Million & CAGR)
8.6.6 Middle East and Africa Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Million & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Biliary Tract Cancer Market
9.2 Drivers
9.3 Restraints
9.4 Trends
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Porter Analysis
11. Competitive Positioning
11.1 Companies’ Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Biliary Tract Cancer Market
11.4 Company Profiles
11.4.1 Johnson & Johnson
11.4.2 Sanofi
11.4.3 Novartis
11.4.4 Pfizer
11.4.5 Bayer AG
11.4.6 Merck & Co., Inc.
11.4.7 Teva Pharmaceuticals
11.4.8 Eli Lily & Co.
11.4.9 Bristol Myers Squibb
11.4.10 F. Hoffmann-La Roche AG
11.2 Market Position Matrix
11.3 Market Share Analysis of Biliary Tract Cancer Market
11.4 Company Profiles
11.4.1 Johnson & Johnson
11.4.2 Sanofi
11.4.3 Novartis
11.4.4 Pfizer
11.4.5 Bayer AG
11.4.6 Merck & Co., Inc.
11.4.7 Teva Pharmaceuticals
11.4.8 Eli Lily & Co.
11.4.9 Bristol Myers Squibb
11.4.10 F. Hoffmann-La Roche AG
List of Figures
Figure 1: Global Prevalence of Gallbladder and biliary tract cancer, 2021
Figure 2: Global Incidence of Gallbladder and biliary tract cancer, 2021
Figure 3: Global Biliary Tract Cancer Market Size, By Value, 2020-2023 (USD Million)
Figure 4: Global Biliary Tract Cancer Market Size, By Value, 2024-2030 (USD Million)
Figure 5: Global Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 6: Market Attractiveness Analysis of Biliary Tract Cancer Market, By Indication (2025-2030)
Figure 7: Global Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 8: Global Biliary Tract Cancer Market Absolute Opportunity, By Extrahepatic Bile Duct Cancer, 2020-2030 (USD Million)
Figure 9: Global Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 10: Global Biliary Tract Cancer Market Absolute Opportunity, By Intrahepatic Bile Duct Cancer, 2020-2030 (USD Million)
Figure 11: Market Attractiveness Analysis of Biliary Tract Cancer Market, By Therapeutics (2025-2030)
Figure 12: Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 13: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine + Cisplatin, 2020-2030 (USD Million)
Figure 14: Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 15: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine + Cisplatin + Other targeted therapies, 2020-2030 (USD Million)
Figure 16: Global Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 17: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine, 2020-2030 (USD Million)
Figure 18: Global Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 19: Global Biliary Tract Cancer Market Absolute Opportunity, By Other targeted therapies, 2020-2030 (USD Million)
Figure 20: Global Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 21: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine + Other chemotherapy combinations, 2020-2030 (USD Million)
Figure 22: Americas Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 23: Americas Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 24: Americas Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 25: Americas Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 26: Americas Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 27: Americas Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 28: Americas Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 29: Americas Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 30: Americas Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 31: United States Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 32: United States Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 33: United States Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 34: United States Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 35: Canada Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 36: Canada Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 37: Canada Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 38: Canada Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 39: Rest of Americas Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 40: Rest of Americas Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 41: Rest of Americas Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 42: Rest of Americas Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 43: Europe Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 44: Europe Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 45: Europe Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 46: Europe Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 47: Europe Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 48: Europe Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 49: Europe Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 50: Europe Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 51: Europe Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 52: Germany Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 53: Germany Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 54: Germany Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 55: Germany Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 56: United Kingdom Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 57: United Kingdom Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 58: United Kingdom Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 59: United Kingdom Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 60: France Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 61: France Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 62: France Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 63: France Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 64: Italy Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 65: Italy Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 66: Italy Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 67: Italy Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 68: Spain Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 69: Spain Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 70: Spain Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 71: Spain Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 72: Rest of Europe Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 73: Rest of Europe Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 74: Rest of Europe Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 75: Rest of Europe Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 76: Asia Pacific Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 77: Asia Pacific Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 78: Asia Pacific Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 79: Asia Pacific Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 80: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 81: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 82: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 83: Asia Pacific Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 84: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 85: China Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 86: China Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 87: China Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 88: China Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 89: Japan Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 90: Japan Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 91: Japan Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 92: Japan Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 93: India Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 94: India Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 95: India Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 96: India Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 97: Rest of Asia Pacific Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 98: Rest of Asia Pacific Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 99: Rest of Asia Pacific Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 100: Rest of Asia Pacific Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 101: Middle East and Africa Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 102: Middle East and Africa Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 103: Middle East and Africa Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 104: Middle East and Africa Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 105: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 106: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 107: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 108: Middle East and Africa Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 109: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 110: Market Share of Prominent Companies of Biliary Tract Cancer Market, 2023 (%)
Figure 111: Johnson & Johnson Revenue, 2021-2023 (USD Million)
Figure 112: Johnson & Johnson Revenue, By Geographical Segments, 2023 (%)
Figure 113: Johnson & Johnson Revenue, By Business Segments, 2023 (%)
Figure 114: Sanofi Revenues, 2020-2022 (USD Million)
Figure 115: Sanofi Revenues, By Geographic Segments, 2022 (%)
Figure 116: Sanofi Revenue , By Business Segments, 2022 (%)
Figure 117: Novartis Revenues, 2021-2023 (USD Million)
Figure 118: Novartis Revenues, By Geographic Segments, 2023 (%)
Figure 119: Novartis Revenue , By Business Segments, 2023 (%)
Figure 120: Pfizer Revenues, 2020-2022 (USD Million)
Figure 121: Pfizer Revenues, By Business Segments, 2023 (%)
Figure 122: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
Figure 123: Bayer AG Revenues 2021-2023(USD Million)
Figure 124: Bayer AG Revenues, By Geographic Segments, 2023 (%)
Figure 125: Bayer AG Revenues, By Business Segments, 2023 (%)
Figure 126: Merck & Co., Inc. Revenues, 2021-2023 (USD Million)
Figure 127: Merck & Co., Inc. Revenues, By Geographic Segments, 2023 (%)
Figure 128: Merck & Co., Inc. Revenue , By Business Segments, 2023 (%)
Figure 129: Teva Pharmaceuticals Revenues, 2020-2022 (USD Million)
Figure 130: Teva Pharmaceuticals Revenue , By Geographical Segments, 2022 (%)
Figure 131: Eli Lily & Co. Revenues, 2021-2023 (USD Million)
Figure 132: Eli Lily & Co. Revenues, By Geographic Segments, 2023 (%)
Figure 133: Eli Lily & Co. Revenue , By Business Segments, 2023 (%)
Figure 134: Bristol Myers Squibb Revenues, 2021-2023 (USD Million)
Figure 135: Bristol Myers Squibb Revenues, By Geographic Segments, 2023 (%)
Figure 136: Bristol Myers Squibb Revenue , By Products, 2023 (%)
Figure 137: Roche Revenues, 2021-2023 (USD Million)
Figure 138: Roche Revenue , By Sales Division, 2023 (%)
Figure 139: Roche Revenue , By Geographical Segment, 2023 (%)
Figure 2: Global Incidence of Gallbladder and biliary tract cancer, 2021
Figure 3: Global Biliary Tract Cancer Market Size, By Value, 2020-2023 (USD Million)
Figure 4: Global Biliary Tract Cancer Market Size, By Value, 2024-2030 (USD Million)
Figure 5: Global Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 6: Market Attractiveness Analysis of Biliary Tract Cancer Market, By Indication (2025-2030)
Figure 7: Global Biliary Tract Cancer Market Size, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 8: Global Biliary Tract Cancer Market Absolute Opportunity, By Extrahepatic Bile Duct Cancer, 2020-2030 (USD Million)
Figure 9: Global Biliary Tract Cancer Market Size, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 10: Global Biliary Tract Cancer Market Absolute Opportunity, By Intrahepatic Bile Duct Cancer, 2020-2030 (USD Million)
Figure 11: Market Attractiveness Analysis of Biliary Tract Cancer Market, By Therapeutics (2025-2030)
Figure 12: Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 13: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine + Cisplatin, 2020-2030 (USD Million)
Figure 14: Global Biliary Tract Cancer Market Size, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 15: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine + Cisplatin + Other targeted therapies, 2020-2030 (USD Million)
Figure 16: Global Biliary Tract Cancer Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 17: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine, 2020-2030 (USD Million)
Figure 18: Global Biliary Tract Cancer Market Size, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 19: Global Biliary Tract Cancer Market Absolute Opportunity, By Other targeted therapies, 2020-2030 (USD Million)
Figure 20: Global Biliary Tract Cancer Market Size, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 21: Global Biliary Tract Cancer Market Absolute Opportunity, By Gemcitabine + Other chemotherapy combinations, 2020-2030 (USD Million)
Figure 22: Americas Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 23: Americas Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 24: Americas Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 25: Americas Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 26: Americas Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 27: Americas Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 28: Americas Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 29: Americas Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 30: Americas Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 31: United States Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 32: United States Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 33: United States Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 34: United States Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 35: Canada Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 36: Canada Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 37: Canada Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 38: Canada Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 39: Rest of Americas Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 40: Rest of Americas Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 41: Rest of Americas Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 42: Rest of Americas Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 43: Europe Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 44: Europe Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 45: Europe Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 46: Europe Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 47: Europe Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 48: Europe Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 49: Europe Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 50: Europe Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 51: Europe Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 52: Germany Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 53: Germany Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 54: Germany Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 55: Germany Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 56: United Kingdom Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 57: United Kingdom Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 58: United Kingdom Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 59: United Kingdom Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 60: France Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 61: France Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 62: France Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 63: France Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 64: Italy Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 65: Italy Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 66: Italy Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 67: Italy Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 68: Spain Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 69: Spain Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 70: Spain Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 71: Spain Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 72: Rest of Europe Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 73: Rest of Europe Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 74: Rest of Europe Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 75: Rest of Europe Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 76: Asia Pacific Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 77: Asia Pacific Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 78: Asia Pacific Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 79: Asia Pacific Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 80: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 81: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 82: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 83: Asia Pacific Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 84: Asia Pacific Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 85: China Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 86: China Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 87: China Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 88: China Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 89: Japan Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 90: Japan Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 91: Japan Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 92: Japan Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 93: India Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 94: India Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 95: India Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 96: India Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 97: Rest of Asia Pacific Biliary Tract Cancer Market, By Value, 2020-2030 (USD Millions & CAGR)
Figure 98: Rest of Asia Pacific Biliary Tract Cancer Market Value, By Indication, 2023 (USD Million)
Figure 99: Rest of Asia Pacific Biliary Tract Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 100: Rest of Asia Pacific Biliary Tract Cancer Market Share, By Therapeutics, By Value, 2023 (%)
Figure 101: Middle East and Africa Biliary Tract Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 102: Middle East and Africa Biliary Tract Cancer Market Share, By Indication, 2023 (%)
Figure 103: Middle East and Africa Biliary Tract Cancer Market, By Extrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 104: Middle East and Africa Biliary Tract Cancer Market, By Intrahepatic Bile Duct Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 105: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine + Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 106: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine + Cisplatin + Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 107: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 108: Middle East and Africa Biliary Tract Cancer Market, By Other targeted therapies, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 109: Middle East and Africa Biliary Tract Cancer Market, By Gemcitabine + Other chemotherapy combinations, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 110: Market Share of Prominent Companies of Biliary Tract Cancer Market, 2023 (%)
Figure 111: Johnson & Johnson Revenue, 2021-2023 (USD Million)
Figure 112: Johnson & Johnson Revenue, By Geographical Segments, 2023 (%)
Figure 113: Johnson & Johnson Revenue, By Business Segments, 2023 (%)
Figure 114: Sanofi Revenues, 2020-2022 (USD Million)
Figure 115: Sanofi Revenues, By Geographic Segments, 2022 (%)
Figure 116: Sanofi Revenue , By Business Segments, 2022 (%)
Figure 117: Novartis Revenues, 2021-2023 (USD Million)
Figure 118: Novartis Revenues, By Geographic Segments, 2023 (%)
Figure 119: Novartis Revenue , By Business Segments, 2023 (%)
Figure 120: Pfizer Revenues, 2020-2022 (USD Million)
Figure 121: Pfizer Revenues, By Business Segments, 2023 (%)
Figure 122: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
Figure 123: Bayer AG Revenues 2021-2023(USD Million)
Figure 124: Bayer AG Revenues, By Geographic Segments, 2023 (%)
Figure 125: Bayer AG Revenues, By Business Segments, 2023 (%)
Figure 126: Merck & Co., Inc. Revenues, 2021-2023 (USD Million)
Figure 127: Merck & Co., Inc. Revenues, By Geographic Segments, 2023 (%)
Figure 128: Merck & Co., Inc. Revenue , By Business Segments, 2023 (%)
Figure 129: Teva Pharmaceuticals Revenues, 2020-2022 (USD Million)
Figure 130: Teva Pharmaceuticals Revenue , By Geographical Segments, 2022 (%)
Figure 131: Eli Lily & Co. Revenues, 2021-2023 (USD Million)
Figure 132: Eli Lily & Co. Revenues, By Geographic Segments, 2023 (%)
Figure 133: Eli Lily & Co. Revenue , By Business Segments, 2023 (%)
Figure 134: Bristol Myers Squibb Revenues, 2021-2023 (USD Million)
Figure 135: Bristol Myers Squibb Revenues, By Geographic Segments, 2023 (%)
Figure 136: Bristol Myers Squibb Revenue , By Products, 2023 (%)
Figure 137: Roche Revenues, 2021-2023 (USD Million)
Figure 138: Roche Revenue , By Sales Division, 2023 (%)
Figure 139: Roche Revenue , By Geographical Segment, 2023 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Total Incident Cases of Biliary tract cancers in the 7 Major Markets 2020-2024
Table A3: United States Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A4: United States Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A5: United States Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A6: United States Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A7: Canada Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A8: Canada Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A9: Canada Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A10: Canada Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A11: Rest of Americas Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A12: Rest of Americas Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A13: Rest of Americas Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A14: Rest of Americas Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A15: Germany Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A16: Germany Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A17: Germany Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A18: Germany Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A19: United Kingdom Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A20: United Kingdom Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A21: United Kingdom Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A22: United Kingdom Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A23: France Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A24: France Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A25: France Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A26: France Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A27: Italy Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A28: Italy Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A29: Italy Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A30: Italy Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A31: Spain Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A32: Spain Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A33: Spain Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A34: Spain Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A35: Rest of Europe Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A36: Rest of Europe Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A37: Rest of Europe Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A38: Rest of Europe Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A39: China Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A40: China Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A41: China Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A42: China Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A43: Japan Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A44: Japan Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A45: Japan Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A46: Japan Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A47: India Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A48: India Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A49: India Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A50: India Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A51: Rest of Asia Pacific Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A52: Rest of Asia Pacific Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A53: Rest of Asia Pacific Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A54: Rest of Asia Pacific Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A55: Johnson & Johnson Key Financials, 2021-2023
Table A56: Sanofi Key Financials, 2020-2022
Table A57: Novartis Key Financials, 2021-2023
Table A58: Pfizer Key Financials, 2021-2023
Table A59: Bayer AG Key Financials, 2021-2023
Table A60: Merck & Co., Inc. Key Financials, 2021-2023
Table A61: Teva Pharmaceuticals Key Financials, 2021-2023
Table A62: Eli Lily & Co. Key Financials, 2021-2023
Table A63: Bristol Myers Squibb Key Financials, 2021-2023
Table A64: Roche Key Financials, 2021-2023
Table A2: Total Incident Cases of Biliary tract cancers in the 7 Major Markets 2020-2024
Table A3: United States Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A4: United States Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A5: United States Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A6: United States Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A7: Canada Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A8: Canada Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A9: Canada Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A10: Canada Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A11: Rest of Americas Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A12: Rest of Americas Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A13: Rest of Americas Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A14: Rest of Americas Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A15: Germany Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A16: Germany Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A17: Germany Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A18: Germany Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A19: United Kingdom Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A20: United Kingdom Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A21: United Kingdom Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A22: United Kingdom Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A23: France Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A24: France Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A25: France Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A26: France Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A27: Italy Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A28: Italy Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A29: Italy Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A30: Italy Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A31: Spain Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A32: Spain Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A33: Spain Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A34: Spain Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A35: Rest of Europe Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A36: Rest of Europe Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A37: Rest of Europe Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A38: Rest of Europe Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A39: China Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A40: China Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A41: China Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A42: China Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A43: Japan Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A44: Japan Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A45: Japan Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A46: Japan Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A47: India Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A48: India Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A49: India Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A50: India Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A51: Rest of Asia Pacific Biliary Tract Cancer Market, By Indication, By Value, 2020-2023 (USD Million)
Table A52: Rest of Asia Pacific Biliary Tract Cancer Market, By Indication, By Value, 2025-2030 (USD Million)
Table A53: Rest of Asia Pacific Biliary Tract Cancer Market, By Therapeutics, By Value, 2020-2023 (USD Million)
Table A54: Rest of Asia Pacific Biliary Tract Cancer Market, By Therapeutics, By Value, 2025-2030 (USD Million)
Table A55: Johnson & Johnson Key Financials, 2021-2023
Table A56: Sanofi Key Financials, 2020-2022
Table A57: Novartis Key Financials, 2021-2023
Table A58: Pfizer Key Financials, 2021-2023
Table A59: Bayer AG Key Financials, 2021-2023
Table A60: Merck & Co., Inc. Key Financials, 2021-2023
Table A61: Teva Pharmaceuticals Key Financials, 2021-2023
Table A62: Eli Lily & Co. Key Financials, 2021-2023
Table A63: Bristol Myers Squibb Key Financials, 2021-2023
Table A64: Roche Key Financials, 2021-2023
Companies Mentioned
- Johnson & Johnson
- Sanofi
- Novartis
- Pfizer
- Bayer AG
- Merck & Co., Inc.
- Teva Pharmaceuticals
- Eli Lily & Co.
- Bristol Myers Squibb
- F. Hoffmann-La Roche AG
